相关实验视频

Updated: Jun 13, 2025

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

对EGFR突变非小细胞肺癌患者的外科免疫疗法:意想不到的潜在益处

Feifei Teng¹, Xiao Ju², Zhenhua Gao²

¹Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

Biochimica et biophysica acta. Reviews on cancer

|October 16, 2024

概括

外科手术期间的免疫检查点抑制剂在早期EGFR突变非小细胞肺癌中显示出生存益处,与晚期相反. 对生物标志物和机制的进一步研究对于优化治疗策略至关重要.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
遗传学遗传学是一个

背景情况:

免疫疗法可以改善晚期非小细胞肺癌 (NSCLC) 的存活率.
免疫疗法在早期NSCLC,特别是EGFR突变型的有效性仍然存在争议.
瘤进展将免疫环境转向免疫抑制,可能影响治疗疗效.

研究的目的:

评估外科手术期间免疫检查点抑制剂 (ICI) 在早期EGFR突变NSCLC中的有效性.
探索ICI在早期EGFR突变NSCLC疗效背后的机制.
确定用于指导外科手术期间管理的预测生物标志物.

主要方法:

对早期EGFR突变性NSCLC的术后治疗方式的新兴数据的审查.
分析包括EGFR突变状态在内的研究,以评估生存益处.
瘤微环境变化和遗传异质性的探索.

主要成果:

在可切除EGFR阳性的NSCLC中观察到外科手术期间ICI的意外生存益处.
这些发现与先进EGFR突变NSCLC的结果形成鲜明对比.
早期的瘤可能具有更响应的抗瘤免疫环境.

结论:

术后ICI在早期EGFR突变NSCLC中显示出有希望的生存益处.
了解免疫微环境和遗传亚克隆是关键.
需要进一步的研究来优化外科手术期间的策略,并确定预测性生物标志物.

关键词:

一个辅助的辅助.欧洲农业基金会 (EGFR) 是一个.免疫检查点抑制剂免疫检查点抑制剂免疫治疗是一种免疫疗法.肺癌是一种肺癌.新辅助剂是一种新辅助剂.

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...